Deutsche Bank Ag\ Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Deutsche Bank Ag\

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $4.76 Million - $8.2 Million	33,200 Added 195.29%	50,200 $12.2 Million
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $117,208 - $158,560	-800 Reduced 4.49%	17,000 $2.54 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $2.7 Million - $3.5 Million	17,800 New	17,800 $3.41 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $9,133 - $11,776	50 New	50 $10,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.